GB2457710A - Thyroxine and its use in weight loss and obesity treatment - Google Patents
Thyroxine and its use in weight loss and obesity treatment Download PDFInfo
- Publication number
- GB2457710A GB2457710A GB0803262A GB0803262A GB2457710A GB 2457710 A GB2457710 A GB 2457710A GB 0803262 A GB0803262 A GB 0803262A GB 0803262 A GB0803262 A GB 0803262A GB 2457710 A GB2457710 A GB 2457710A
- Authority
- GB
- United Kingdom
- Prior art keywords
- weight loss
- thyroxine
- body fat
- micrograms
- average
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 title abstract description 7
- 229940034208 thyroxine Drugs 0.000 title abstract description 7
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 title abstract description 7
- 230000004580 weight loss Effects 0.000 title abstract description 5
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 4
- 230000000747 cardiac effect Effects 0.000 abstract 3
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Thyroxine was used at doses ranging from 50 micrograms to 100 micrograms depending on cardiac fitness and age to reduce body fat and thereby induce weight loss. Patients above 50 years of age and with no pre-existing cardiac conditions where given 50 micrograms once daily and those less than 50 with no cardiac conditions were given 100 micrograms once daily. After 6 weeks the body fat proportions in a younger patient group dropped from an average body fat of 27% to 9% and weight loss was dramatic. In an older patient group body fat proportion which was initially at an average of 41% dropped to 22% while weight loss on average was 14kg per person.
Description
Thyroxine is currently a replacement hormone used for the treatment of hypothyroxidism. As the name suggests ills a lack or low level of Thyroxine (a naturally occurring hormone in the human endocrine system). Thyroxine has amongst many functions, the action of hastening many chemical reactions throughout all cells of the human body. It also plays a role in protein synthesis from many substrates including lipids.
It's main function and what I am concerned with here is it's function at increasing the basal metabolic rate and how this function it has can help to aid weight loss but also I am concerned with the fact that circulating fatty acids and glucose which would ultimately deposit themselves ultimately as adipose (Fat) tissue beneath the skin are use as substrates with the help of thyroxine in the production of protein.
By virtue of the above Thyroxine can aid slimming.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0803262A GB2457710A (en) | 2008-02-25 | 2008-02-25 | Thyroxine and its use in weight loss and obesity treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0803262A GB2457710A (en) | 2008-02-25 | 2008-02-25 | Thyroxine and its use in weight loss and obesity treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0803262D0 GB0803262D0 (en) | 2008-04-02 |
| GB2457710A true GB2457710A (en) | 2009-08-26 |
Family
ID=39284390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0803262A Withdrawn GB2457710A (en) | 2008-02-25 | 2008-02-25 | Thyroxine and its use in weight loss and obesity treatment |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2457710A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1354263A (en) * | 1971-06-03 | 1974-06-05 | Theranol Lab | Therapeutic composition |
| GB1435916A (en) * | 1972-05-11 | 1976-05-19 | Beecham Group Ltd | Pharmaceutical weight-reducing compositions |
| WO1997017951A1 (en) * | 1995-11-14 | 1997-05-22 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
| US20030203968A1 (en) * | 2001-02-15 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions and methods |
-
2008
- 2008-02-25 GB GB0803262A patent/GB2457710A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1354263A (en) * | 1971-06-03 | 1974-06-05 | Theranol Lab | Therapeutic composition |
| GB1435916A (en) * | 1972-05-11 | 1976-05-19 | Beecham Group Ltd | Pharmaceutical weight-reducing compositions |
| WO1997017951A1 (en) * | 1995-11-14 | 1997-05-22 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
| US20030203968A1 (en) * | 2001-02-15 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0803262D0 (en) | 2008-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BOLAND et al. | Effects of cortisone acetate on rheumatoid arthritis | |
| Faryadi | The magnificent effect of magnesium to human health: a critical review | |
| Yin et al. | Digestion rate of dietary starch affects the systemic circulation of lipid profiles and lipid metabolism-related gene expression in weaned pigs | |
| JP6894991B2 (en) | Cosmetic composition containing mint vinegar as an active ingredient | |
| RU2008134874A (en) | METHOD FOR INCREASING DRY MUSCULAR MASS AND REDUCING FAT TISSUE | |
| JP6954997B2 (en) | Composition for treating partial obesity and microneedles containing it | |
| KR101656536B1 (en) | Paeoniflorin preparations and uses thereof for fat reduction | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| CN104146908A (en) | Body building and weight reducing peony composite essential oil and preparation method thereof | |
| JP2018514554A (en) | Cosmetic methods and therapeutic uses for reducing fat | |
| CN102839206A (en) | Preparation method for promoting self generation of human bone marrow hematopoietic stem cells | |
| US20210046161A1 (en) | Skin ointment for treating labia minora skin | |
| GB2457710A (en) | Thyroxine and its use in weight loss and obesity treatment | |
| Micossi et al. | Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CSII) | |
| PH12014000244B1 (en) | Method for the treatment of hypercholesterolemia | |
| RU2792400C1 (en) | Method of rehabilitation of patients after transferred pneumonia | |
| CN102697855A (en) | Medicinal composition for treating skin diseases | |
| US20230025468A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
| Li et al. | The influence of Dunqiang Qigong on hearing and blood sugar lever of patients with diabetes deafness | |
| Bischoff et al. | The importance of maximizing vitamin D in the elderly diet with respect to function and falls | |
| CN107335052A (en) | For treating the formulation product of diabetes | |
| Gafni et al. | A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX-305) in Autosomal Dominant Hypocalcemia Type 1 (ADH1) | |
| Weerasinghe | Metabolic Inflexibility as a root cause of many chronic diseases | |
| Laway et al. | IFAP syndrome with rickets and normal vitamin D status | |
| KR20160109782A (en) | A Patch Have Dissolve Skill of Cellulite and Underwear Skill for Revision |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |